Quality still doesn't pay in heart failure management

Journal of Cardiac Failure

Volumn 9, Issue 4, 2003, Pages 263-265

  Whellan, David J ^a   Mark, Daniel B ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL PRACTICE; CLINICAL TRIAL; EDITORIAL; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEART FAILURE; HOSPITALIZATION; HUMAN; MEDICARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL;

EID: 0041360019     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2003.52     Document Type: Article

References (19)

1. Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs. JAMA 1996;276: 1473-9.
2. American Heart Association. 2002 heart and stroke statistical update. Dallas, TX, American Heart Association; 2003.
3. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45:968-74.
4. Thomas L. The lives of a cell. Notes of a biology watcher. New York: Penguin Books; 1978.
5. Krumholz HM, Parent EM, Tu N, Vaccarina V, Wang Y, Radford MJ. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997;157:99-104.
6. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine I. Circulation 2002;106:516-20.
7. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
8. The CIBIS II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
9. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295-302.
10. st century. Washington, DC: Institute of Medicine; 2001.
11. Whellan DJ, Cohen EJ, Matchar DB, Califf RM. Disease management in healthcare organizations: results of in-depth interviews with disease management decision makers. Am J Manag Care 2002;8:633-41.
12. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001;110: 378-84.
13. McDonald K, Ledwidge M. Heart failure management programs: can we afford to ignore the inpatient phase of care? J Card Fail 2003;9:258-62.
14. McDonald K, Ledwidge M, Cahill J, Kelly J, Quigley P, Maurer B, et al. Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzyme inhibitor dose at discharge. Eur J Heart Fail 2001;3:209-15.
15. Krumholz HM, Baker DW, Ashton CM, Dunbar SB, Friesinger GC, Havranek EP, et al. Evaluating quality of care for patients with heart failure. Circulation 2000;101: E122-40.
16. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
17. Havranek EP, Krumholz HM, Dudley RA, Adams K, Gregory D, Lindenfeld J, et al. Aligning quality and payment for heart failure care: defining the challenges. J Card Fail 2003;9:251-4.
18. American Hospital Association. Trendwatch: trends affecting hospitals and healthcare systems. Washington, DC: American Hospital Association; 2003.
19. Heinrich J. Nursing workforce: emerging nurse shortages due to multiple factors. United States General Accounting Office. GAO-01-944. Washington, DC; 2001.